Among the new CRBN-based PROTACs, PROTAC 2 (Table 2) effectively degraded AR protein with a degradation concentration 50% of 12.5 nM and maximum degradation of 93% in LNCaP prostate cancer cells. Here, AR is linked to prostate cancer.